developing second other-site primary cancers, or they may redevelop CRC after primary cancer of other organs. Although synchronous and metachronous CRC are now well known to all colorectal surgeons, second other-site primary cancers accompanying CRC are unfamiliar to most colorectal physicians. Knowledge of the clinical characteristics of these second primary cancers becomes important especially during postoperative surveillance of these patients. In this article, we describe our clinical experience of CRC patients with other associated primary cancers, and review the literature.
MATERIALS AND METHODS
Between January 1998 and December 2004, 1,031 sporadic CRC patients underwent surgical treatment at the Department of Surgery of Kaohsiung Medical University Hospital. Among these patients, CRC was accompanied by cancer of other organs in 17 (1.65%), either synchronously or metachronously. The inclusion criteria were that each tumor had to have a definite histologic picture of malignancy, and clearly no origin of metastasis from another tumor. Second cancers detected within 1 year after the detection of the initial cancers were regarded as synchronous cancers. The medical records including patients' demographics, clinical and pathologic features, operative details, and outcomes were retrospectively reviewed. Clinical stage and pathologic features of primary CRC were defined according to the criteria of the American Joint Commission on Cancer [3] . Table 1 lists the demographics and clinical features of CRC patients with other primary cancers. There were four synchronous and 13 metachronous multiple cancer patients. The group comprised six men and 11 women with ages ranging from 47 to 88 years (median age, 66 years). The most common site of CRC was the sigmoid colon. Primary cancers of other organs were six breast cancers (35.2%) and six gastric cancers (35.2%). The remaining six cancers included one lung cancer, one thyroid cancer, one cervical cancer, one ovarian cancer, one skin cancer, and one urinary bladder cancer.
RESULTS
One patient had triple primary cancers involving the stomach, breast, and colon.
The intervals between the development of multiple primary cancers ranged from 2 to 19 years. The TNM stages of the CRC patients were as follows: five patients were stage I (29.4%), three patients were stage II (17.6%), seven patients were stage III (41.2%), and two patients were stage IV (11.8%). With regard to the histologic types of these tumors, six (35.3%) were well-differentiated carcinoma, eight (47.1 %) were moderately differentiated carcinoma, and three (17.6%) were poorly differentiated carcinoma. Of the 13 metachronous multiple cancer patients, 11 developed subsequent CRC after cancers of other organs, whereas two patients developed subsequent primary cancer after CRC. Most of the synchronous double cancer patients (3/4, 75%) were gastric cancer combined with CRC. Most of the CRC patients (15/17) were diagnosed by colonoscopy due to the presence of hematochezia or gastrointestinal symptoms/signs, while two CRC patients with severe bowel obstruction were diagnosed by abdominal computed tomography ( Table 2 ). The most common clinical symptoms and signs included hematochezia, followed by abdominal pain, constipation, anemia, and ileus. To date, most patients have survived, but two stage IV patients died of CRC due to delayed diagnosis of the disease.
DISCUSSION
CRC is a leading cause of death in the Western world, and it has also become the third leading cause of death from cancer in Taiwan. Survival can be improved if the disease is detected earlier. Cancer-bearing patients are assumed to be at increased risk of developing cancers of other organs [4] . The rapidly increasing rate of CRC in recent years has drawn special attention to this site in terms of synchronous and metachronous malignancies of other organs. In this current investigation, the incidence of a second othersite primary cancer is 1.65%, which is within the range of 1.26-3.3% from previous reports [5] [6] [7] .
Of these 17 cases, breast and gastric cancer patients had the highest risk of second cancer for CRC. Our results are consistent with those of a Japanese research group [5, 8] , where gastric cancer predominates among CRC patients with primary cancer of other organs. Ueno et al indicated that when colon cancer was combined with other cancers, stomach cancer (1.4%) was the most frequently encountered neoplasm, followed by breast cancer (0.4%); and when rectal cancer was combined with other cancers, stomach cancer (0.6%) was also the most frequently encountered neoplasm, but this was followed by lung cancer (0.5%) [5] . Consequently, we should closely follow up and ascertain the possibility of developing secondary CRC among gastric and breast cancer patients postoperatively. Conversely, our incidence of lung cancer together with CRC is only 0.1%, which is far less than the Japanese study. Another research group from Taiwan [7] observed that the most common second other-site primary cancer in CRC patients was the liver, and this was followed by the stomach. Recently, the decreasing incidence of hepatoma in Taiwan may possibly explain this phenomenon. Furthermore, there is an increased risk of developing breast or reproductive organ cancer in women who survive CRC [9] [10] [11] [12] . Screening for colorectal tumors in women with a past history of breast, uterine, or ovarian malignancies is suggested [12] . It was reported that cervical cancer was the most predominant malignancy associated with CRC, followed by gastric cancer in the past [13] . However, with the increasing incidence of breast cancer in developed countries in recent years, breast cancer has become the highest risk malignancy accompanying CRC. Most patients have the symptoms and signs of hematochezia or bowel habit change, and the disease is usually diagnosed by colonoscopy. The essentials of colonoscopy for patients with previous malignancy must be kept in mind. A significantly higher proportion of TNM stage I CRC (29.4%) would be responsible for the favorable clinical outcomes of these patients in our investigations. Early diagnosis and surgical intervention should also be emphasized, though two patients were diagnosed as late as stage IV. We observed three gastric cancers of four synchronous second other-site primary cancers among our CRC patients, and these findings raised an issue of performing upper gastrointestinal endoscopy before management of CRC. Ueno et al suggested that all CRC patients should undergo screening by upper gastrointestinal endoscopy before operation [5] . In addition, they recommend repeated upper gastrointestinal endoscopy at 2-year intervals during the first 5 years after operation. However, its cost-effectiveness remains to be further evaluated. We suggest that CRC patients with gastrointestinal symptoms or signs should be carefully evaluated and checked up for the necessity of upper gastrointestinal endoscopy in advance. Precursor lesions (adenomatous polyps) almost always precede the development of the neoplasm by several years. In our study, one gastric cancer patient who had undergone transanal polypectomy 15 years previously and who was lost to follow-up unfortunately developed unresectable rectal cancer later.
Systematic surveillance for second cancer is essential after cancer surgery. A good surveillance program should be cost-effective, and more detailed analysis is mandatory for the high-risk sites of developing second cancers. Breast and gastric cancer patients in particular have high risk for second cancers of CRC. Patients presenting with hematochezia or other gastrointestinal symptoms/signs should be carefully evaluated. 
